• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Abon Biopharm (Hangzhou) Co., Ltd. Close out Letter 10/16/12


Department of Health and Human Services logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
  10903 New Hampshire Avenue
Silver Spring, MD 20993 


October 16, 2012

Mr. Gao Fei, General Manager
Abon Biopharm (Hangzhou) Co. Ltd.
# 198 12th Street East
Hangzhou Economic & Technological Development Area
Hangzhou, China 310018

Dear Mr. Gao:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter [CMS 151292, dated December 22, 2010]. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.



Office of In Vitro Diagnostics and
Radiological Health
Center for Devices and
Radiological Health